Hematopoetic Stem Cell Transplantation in Neutrophil Disorders: Severe Congenital Neutropenia, Leukocyte Adhesion Deficiency and Chronic Granulomatous Disease

Until further progress will occur in the field of gene therapy, the only curative treatment available in severe congenital neutropenia, leukocyte adhesion deficiency, and chronic granulomatous disease is allogeneic hematopoietic stem cell transplantation (HSCT). This review summarizes the current da...

Full description

Saved in:
Bibliographic Details
Published in:Clinical reviews in allergy & immunology 2010-02, Vol.38 (1), p.61-67
Main Authors: Elhasid, Ronit, Rowe, Jacob M
Format: Article
Language:English
Subjects:
Adult
Allergology
Child
Child, Preschool
Chronic granulomatous disease
Data processing
Donors
Female
Gene therapy
Genetic disorders
Granulomatous Disease, Chronic - therapy
Health aspects
Hematopoietic stem cell transplantation (HSCT)
Hematopoietic Stem Cell Transplantation - adverse effects
Hematopoietic Stem Cell Transplantation - methods
Hematopoietic stem cells
Humans
Immunology
Internal Medicine
Leukocyte adhesion deficiency
Leukocyte-Adhesion Deficiency Syndrome - therapy
Leukocytes (neutrophilic)
Male
Medicine
Medicine & Public Health
Neutropenia
Neutropenia - congenital
Neutropenia - therapy
Severe congenital neutropenia
stem cell transplantation
Stem cells
Toxicity
Transplantation
Transplantation, Homologous - adverse effects
Transplantation, Homologous - methods
Treatment Outcome
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Until further progress will occur in the field of gene therapy, the only curative treatment available in severe congenital neutropenia, leukocyte adhesion deficiency, and chronic granulomatous disease is allogeneic hematopoietic stem cell transplantation (HSCT). This review summarizes the current data regarding indications for transplantation in each disease, treatment results using related and unrelated donors, as well as toxicity of HSCT in the above diseases.
ISSN:1080-0549
1559-0267
DOI:10.1007/s12016-009-8129-y